Abstract
Preeclampsia is the leading cause of death and morbidity worldwide for the mother and fetus during pregnancy. Preeclampsia does not only affect the mother and the baby during pregnancy, but can also have long-term effects, such as the increased risk of hypertension and cardiovascular disease on the offspring and the postpartum mother later in life. The exact cause of preeclampsia is unknown, but women with preeclampsia have elevated concentrations of agonistic autoantibodies against the angiotensin II type 1 receptor (AT1-AA). These AT1-AA’s through multiple studies have shown to play a significant role in the pathology and possible genesis of preeclampsia. This review will discuss the discovery of AT1-AAs and the role of AT1-AAs in the pathophysiology of preeclampsia. This review will also discuss future therapeutic approaches towards the AT1-AA to prevent adverse pregnancy outcomes. Furthermore, we will examine the relationship between AT1-AA induced hypertension associated with increased oxidative stress, antiangiogenic factors (such as soluble fms-related tyrosine kinase-1 (sFlt-1), endothelin-1 (ET-1), inflammation, endothelial dysfunction, and reduced renal function. Understanding the pathological role of AT1-AAs in hypertensive pregnancies is important as we search for novel therapies to manage preeclampsia.
Keywords: Preeclampsia, angiotensin II type 1 receptor autoantibody (AT1-AA), oxidative stress, renal function, endothelin.
Current Pharmaceutical Biotechnology
Title:The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia
Volume: 19 Issue: 10
Author(s): Nathan Campbell, Babbette LaMarca*Mark W. Cunningham Jr
Affiliation:
- Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, MS,United States
Keywords: Preeclampsia, angiotensin II type 1 receptor autoantibody (AT1-AA), oxidative stress, renal function, endothelin.
Abstract: Preeclampsia is the leading cause of death and morbidity worldwide for the mother and fetus during pregnancy. Preeclampsia does not only affect the mother and the baby during pregnancy, but can also have long-term effects, such as the increased risk of hypertension and cardiovascular disease on the offspring and the postpartum mother later in life. The exact cause of preeclampsia is unknown, but women with preeclampsia have elevated concentrations of agonistic autoantibodies against the angiotensin II type 1 receptor (AT1-AA). These AT1-AA’s through multiple studies have shown to play a significant role in the pathology and possible genesis of preeclampsia. This review will discuss the discovery of AT1-AAs and the role of AT1-AAs in the pathophysiology of preeclampsia. This review will also discuss future therapeutic approaches towards the AT1-AA to prevent adverse pregnancy outcomes. Furthermore, we will examine the relationship between AT1-AA induced hypertension associated with increased oxidative stress, antiangiogenic factors (such as soluble fms-related tyrosine kinase-1 (sFlt-1), endothelin-1 (ET-1), inflammation, endothelial dysfunction, and reduced renal function. Understanding the pathological role of AT1-AAs in hypertensive pregnancies is important as we search for novel therapies to manage preeclampsia.
Export Options
About this article
Cite this article as:
Campbell Nathan , LaMarca Babbette *, Cunningham Jr W. Mark , The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia, Current Pharmaceutical Biotechnology 2018; 19 (10) . https://dx.doi.org/10.2174/1389201019666180925121254
DOI https://dx.doi.org/10.2174/1389201019666180925121254 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Retrospective Study of Drug Induced Cutaneous Adverse Reactions (CADR) in Patients Attending a Tertiary Care Hospital
Current Drug Safety Herbal Immunomodulators - A Remedial Panacea for Designing and Developing Effective Drugs and Medicines: Current Scenario and Future Prospects
Current Drug Metabolism Development of a Novel Nanocomposite Based on Reduced Graphene Oxide/Chitosan/Au/ZnO and Electrochemical Sensor for Determination of Losartan
Current Analytical Chemistry Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Orekhov`s Method: Reassessment of In vitro Lipid Uptake Assays
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets Pharmacology and Literature Review Based on Related Death and Non-Fatal Case Reports of the Benzofurans and Benzodifurans Designer Drugs
Current Pharmaceutical Design Postmenopausal Hypertension: Insights from Rat Models
Current Hypertension Reviews Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Other Activities
Current Bioactive Compounds Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews Involvement of Dietary Bioactive Proteins and Peptides in Autism Spectrum Disorders
Current Protein & Peptide Science Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture
Current Drug Safety Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science TRH/TRH-R1 Receptor Signaling in the Brain Medulla as a Pathway of Vagally Mediated Gut Responses During the Cephalic Phase
Current Pharmaceutical Design Prolylcarboxypeptidase Independently Activates Plasma Prekallikrein (Fletcher Factor)
Current Molecular Medicine Optimization and Validation of Polyherbal Formulation by Applying Boxbehnken Design for the Treatment of Inflammatory Bowel Disease in Experimental Animals
Current Drug Therapy